Ignite Creation Date:
2024-05-06 @ 12:31 PM
Last Modification Date:
2024-10-26 @ 1:00 PM
Study NCT ID:
NCT03785249
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2018-12-18
Brief Title:
Phase 12 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Sponsor:
Mirati Therapeutics Inc
Organization:
Mirati Therapeutics Inc
Organization Data
Organization:
Mirati Therapeutics Inc
Class:
INDUSTRY
Study ID:
CA239-0008
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Mirati Therapeutics Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None